Chromium (D-phenylalanine)3 improves obesity-induced cardiac contractile defect in ob/ob mice

Objective: Low‐molecular weight chromium compounds, such as chromium picolinate Cr(pic)₃], improve insulin sensitivity, although toxicity is a concern. We synthesized a novel chromium complex, chromium (d ‐phenylalanine)₃ Cr(d ‐phe)₃], in an attempt to improve insulin sensitivity with reduced toxicity. The aim of this study was to compare the two chromium compounds on cardiac contractile function in ob/ob obese mice. Research Methods and Procedures: C57BL lean and ob/ob obese mice were randomly divided into three groups: H₂O, Cr(d ‐phe)₃, or Cr(pic)₃ (45 µg/kg per day orally for 6 months). Results: The glucose tolerance test displayed improved glucose clearance by Cr(d ‐phe)₃ but not Cr(pic)₃. Myocytes from ob/ob mice exhibited depressed peak shortening (PS) and maximal velocity of shortening/relengthening (±dL/dt), prolonged time‐to‐PS and time‐to‐90% relengthening (TR90), reduced electrically stimulated rise in intracellular Ca²⁺ (Δfura‐2 fluorescence intensity), and slowed intracellular Ca²⁺ decay. Although a 3‐month Cr(d ‐phe)₃ treatment for a separate group of ob/ob and lean 2‐month‐old mice only rectified reduced ±dL/dt in ob/ob mice, all mechanical and intracellular Ca²⁺ abnormalities were significantly attenuated or ablated by 6 months of Cr(d ‐phe)₃ but not Cr(pic)₃ treatment (except TR90). Sarco(endo)plasmic reticulum Ca²⁺ ATPase activity and Na⁺‐Ca²⁺ exchanger expression were depressed in ob/ob mice, which were reversed by both Cr(d ‐phe)₃ and Cr(pic)₃, with a more pronounced effect from Cr(d ‐phe)₃. Cr(d ‐phe)₃ corrected reduced insulin‐stimulated glucose uptake and improved basal phosphorylation of Akt and insulin receptor, as well as insulin‐stimulated phosphorylation of Akt and insulin receptor in ob/ob myocytes. Heart homogenates from ob/ob mice had enhanced oxidative stress and protein carbonyl formation compared with the lean group, which were attenuated by both Cr(d ‐phe)₃ and Cr(pic)₃. Discussion: Our data suggest that the new Cr(d ‐phe)₃ compound possesses better cardio‐protective and insulin‐sensitizing properties against obesity.